Administration, Cutaneous
"Administration, Cutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The application of suitable drug dosage forms to the skin for either local or systemic effects.
| Descriptor ID |
D000279
|
| MeSH Number(s) |
E02.319.267.120.060
|
| Concept/Terms |
Administration, Cutaneous- Administration, Cutaneous
- Cutaneous Administration, Drug
- Cutaneous Administrations, Drug
- Drug Administration, Cutaneous
- Administration, Cutaneous Drug
- Administrations, Cutaneous Drug
- Cutaneous Drug Administrations
- Drug Administrations, Cutaneous
- Cutaneous Drug Administration
- Dermal Administration
- Drug Administration, Dermal
- Skin Administration, Drug
- Drug Skin Administrations
- Skin Administrations, Drug
- Skin Drug Administration
- Skin Drug Administrations
- Administration, Dermal
- Administrations, Dermal
- Dermal Administrations
- Cutaneous Administration
- Administrations, Cutaneous
- Cutaneous Administrations
- Dermal Drug Administration
- Administration, Dermal Drug
- Administrations, Dermal Drug
- Dermal Drug Administrations
- Drug Administrations, Dermal
Administration, Transcutaneous- Administration, Transcutaneous
- Administrations, Transcutaneous
- Transcutaneous Administrations
- Administration, Transdermal
- Administrations, Transdermal
- Transdermal Administrations
- Transdermal Administration
- Transcutaneous Administration
Percutaneous Administration- Percutaneous Administration
- Administration, Percutaneous
- Administrations, Percutaneous
- Percutaneous Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Cutaneous".
Below are MeSH descriptors whose meaning is more specific than "Administration, Cutaneous".
This graph shows the total number of publications written about "Administration, Cutaneous" by people in this website by year, and whether "Administration, Cutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 5 | 5 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 5 | 5 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Cutaneous" by people in Profiles.
-
Epicutaneous immunotherapy: A review of safety and efficacy. Pediatr Allergy Immunol. 2025 Apr; 36(4):e70096.
-
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study). J Allergy Clin Immunol Pract. 2025 May; 13(5):1190-1200.e3.
-
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. J Allergy Clin Immunol Pract. 2025 May; 13(5):1176-1187.e7.
-
Current and future perspectives on the consensus guideline for food protein-induced enterocolitis syndrome (FPIES). Allergol Int. 2024 Apr; 73(2):188-195.
-
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023 05 11; 388(19):1755-1766.
-
Skin-specific knockdown of hyaluronan in mice by an optimized topical 4-methylumbelliferone formulation. Drug Deliv. 2021 Dec; 28(1):422-432.
-
Food immunotherapy: Choosing wisely. Clin Exp Allergy. 2021 01; 51(1):9-13.
-
Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther. 2020 12; 108(6):1315-1325.
-
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020 10; 146(4):863-874.
-
Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery. J Drugs Dermatol. 2020 May 01; 19(5):485-486.